Integra Life Sciences(Integra LifeSciences)错过了Q1的期望, Integra LifeSciences missed Q1 expectations, hurting stock despite Q4 beat and improved operations.

Integra Life Sciences报告说,2025年第4季度收入为4.35亿美元,比上一年下降1.7%,每份额收入为0.83美元,殴打估计数字。 Integra LifeSciences reported Q4 2025 revenue of $435 million, a 1.7% decline year-over-year, with earnings per share of $0.83, beating estimates. 该公司修订了其2026年展望,预测收入为1.66亿至1.7亿美元,经调整的EPS为2.30至2.40美元,略低于共识。 The company revised its 2026 outlook, projecting revenue of $1.66–1.7 billion and adjusted EPS of $2.30–2.40, slightly below consensus. 尽管重新启动了积极产品并改进了供应链,但由于Q1指导不力、无现金负流动以及持续关税影响,库存下降。 Despite positive product relaunches and supply chain improvements, the stock fell due to weak Q1 guidance, negative free cash flow, and ongoing tariff impacts.